3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast Cancer
NCT ID: NCT00300508
Last Updated: 2009-05-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
856 participants
INTERVENTIONAL
1996-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Secondary Adjuvant Long Term Study With Arimidex
NCT00295620
Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer
NCT00301457
Survey in Post-menopausal Women Followed up After Treatment With Anastrozole as Adjuvant Therapy
NCT00542594
Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer
NCT00357110
Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer
NCT00530868
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anastrozole
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients with breast cancer after surgery,
* 5 years (+/- 12 months) of prior endocrine therapy
Exclusion Criteria
* unknown or negative receptor status,
* Secondary malignant tumor
80 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AstraZeneca Austria Medical Director, MD
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Amstetten, , Austria
Research Site
Bad Ischl, , Austria
Research Site
Baden, , Austria
Research Site
Bregenz, , Austria
Research Site
Bruck an der Mur, , Austria
Research Site
Dornbirn, , Austria
Research Site
Eisenstadt, , Austria
Research Site
Feldbach, , Austria
Research Site
Feldkirch, , Austria
Research Site
Freistadt, , Austria
Research Site
Fürstenfeld, , Austria
Research Site
Graz, , Austria
Research Site
Güssing, , Austria
Research Site
Hainburg an der Donau, , Austria
Research Site
Hartberg, , Austria
Research site
Hollabrunn, , Austria
Research Site
Horn, , Austria
Research Site
Innsbruck, , Austria
Research Site
Kirchdorf, , Austria
Research Site
Klagenfurt, , Austria
Research Site
Klosterneuburg, , Austria
Research Site
Krems, , Austria
Research Site
Kufstein, , Austria
Research Site
Leoben, , Austria
Research Site
Linz, , Austria
Research Site
Mistelbach, , Austria
Research Site
Mödling, , Austria
Research Site
Neunkirche, , Austria
Research Site
Oberpullendorf, , Austria
Research Site
Oberwart, , Austria
Research Site
Ried im Innkreis, , Austria
Research Site
Rohrbach, , Austria
Research Site
Rottenmann, , Austria
Research Site
Salzburg, , Austria
Research Site
Sankt Pölten, , Austria
Research Site
Sankt Veit an der Glan, , Austria
Research Site
Schärding, , Austria
Research Site
Scheibbs, , Austria
Research Site
Schladming, , Austria
Research Site
Schwarzach, , Austria
Research Site
Spittal an der Drau, , Austria
Research Site
Steyr, , Austria
Research Site
Tulln, , Austria
Research Site
Vienna, , Austria
Research Site
Villach, , Austria
Research Site
Vöcklabruck, , Austria
Research Site
Waidhofen an der Ybbs, , Austria
Research Site
Wels, , Austria
Research Site
Wiener Neustadt, , Austria
Research Site
Wolfsberg, , Austria
Research Site
Zams, , Austria
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Wimmer K, Hlauschek D, Balic M, Pfeiler G, Greil R, Singer CF, Halper S, Steger G, Suppan C, Gampenrieder SP, Helfgott R, Egle D, Filipits M, Jakesz R, Solkner L, Fesl C, Gnant M, Fitzal F. Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting? Breast Cancer Res Treat. 2024 Jun;205(2):227-239. doi: 10.1007/s10549-023-07186-6. Epub 2024 Jan 25.
Gnant M, Pfeiler G, Stoger H, Mlineritsch B, Fitzal F, Balic M, Kwasny W, Seifert M, Stierer M, Dubsky P, Greil R, Steger G, Samonigg H, Fesl C, Jakesz R. The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial. Br J Cancer. 2013 Aug 6;109(3):589-96. doi: 10.1038/bjc.2013.367. Epub 2013 Jul 18.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ABCSG 6A
Identifier Type: -
Identifier Source: secondary_id
1033AU/0001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.